Molecular antimicrobial susceptibility testing in sepsis
Rapidly detecting and identifying pathogens is crucial for appropriate antimicrobial therapy in patients with sepsis. Conventional diagnostic methods have been a great asset to medicine, though they are time consuming and labor intensive. This work will enable healthcare professionals to understand the bacterial community better and enhance their diagnostic capacity by using novel molecular methods that make obtaining quicker, more precise results possible. The authors discuss and critically assess the merits and drawbacks of molecular testing and the added value of these tests, including the shift turnaround time, the implication for clinicians' decisions, gaps in knowledge, future research directions and novel insights or innovations. The field of antimicrobial molecular testing has seen several novel insights and innovations to improve the diagnosis and management of infectious diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Future microbiology - 19(2024) vom: 01. Jan., Seite 61-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martin-Loeches, Ignacio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AST |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fmb-2023-0128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366709542 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366709542 | ||
| 003 | DE-627 | ||
| 005 | 20240214233051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fmb-2023-0128 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM366709542 | ||
| 035 | |a (NLM)38180334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martin-Loeches, Ignacio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular antimicrobial susceptibility testing in sepsis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rapidly detecting and identifying pathogens is crucial for appropriate antimicrobial therapy in patients with sepsis. Conventional diagnostic methods have been a great asset to medicine, though they are time consuming and labor intensive. This work will enable healthcare professionals to understand the bacterial community better and enhance their diagnostic capacity by using novel molecular methods that make obtaining quicker, more precise results possible. The authors discuss and critically assess the merits and drawbacks of molecular testing and the added value of these tests, including the shift turnaround time, the implication for clinicians' decisions, gaps in knowledge, future research directions and novel insights or innovations. The field of antimicrobial molecular testing has seen several novel insights and innovations to improve the diagnosis and management of infectious diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AST | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a MDR | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a bacteremia | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a molecular testing | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a sepsis | |
| 650 | 4 | |a septic shock | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Pereira, João Gonçalves |e verfasserin |4 aut | |
| 700 | 1 | |a Teoh, Tee Keat |e verfasserin |4 aut | |
| 700 | 1 | |a Barlow, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Dortet, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Carrol, Enitan D |e verfasserin |4 aut | |
| 700 | 1 | |a Olgemöller, Ulrike |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Sara E |e verfasserin |4 aut | |
| 700 | 1 | |a Textoris, Julien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future microbiology |d 2006 |g 19(2024) vom: 01. Jan., Seite 61-72 |w (DE-627)NLM171766504 |x 1746-0921 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g day:01 |g month:01 |g pages:61-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fmb-2023-0128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |b 01 |c 01 |h 61-72 | ||